Vortex Spółka z Ograniczoną Odpowiedzialnością (KRS 0000327360, NIP 5851447761) is a Polish company, headquartered in Gdańsk, Pomorskie voivodeship. VORTEX operates in: Other research and experimental development on natural sciences and engineering (PKD 72.19.Z). Industry: Research and development. The company has been listed in the National Court Register since April 7, 2009. VORTEX's most recently reported net revenue was 41.6 M PLN for 2024.
No arrears identified in the analyzed sources
No arrears or bankruptcy proceedings identified in the analyzed sources.
Business profile - Vortex
Identity
- Name
- Vortex Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- April 7, 2009
- Registry status as of
- July 6, 2026
- Latest entry
- July 6, 2026
- Founding act
- 09.11.2010R. REPERTORIUM A NR 4883/2010, KANCELARIA NOTARIALNA ADAM WASAK, 80-437 GDAŃSK, UL. WAJDELOTY 18/1, ASESOR NOT…
Articles of association history (4)
- UMOWA SPÓŁKI Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ SPORZĄDZONA W DNIU 19 LUTY 2009R. PRZEZ NOTARIUSZA ADAMA WASAKA W KANCEKARII NOTARIALNEJ W GDAŃSKU REP. A NR 832/2009
- AKT NOTARIALNY SPORZĄDZONY PRZEZ IZABELĘ GASIN ASESOR NOTARIALNĄ W KANCELARII NOTARIUSZA ADAMA WASAKA ZA NUMEREM A 1256/2010 W DNIU 25 MARCA 2010 ZMIENIAJĄCY PAR.3 UMOWY SPÓŁKI
- November 9, 2010: 09.11.2010R. REPERTORIUM A NR 4883/2010, KANCELARIA NOTARIALNA ADAM WASAK, 80-437 GDAŃSK, UL. WAJDELOTY 18/1, ASESOR NOTARIALNY ANNA DZIDKOWSKA ZASTĘPCA NOTARIUSZA ADAMA WASAKA, ZMIANA PARAGRAFU 6 UMOWY SPÓŁKI.
- 20-12-2024R. REPERTORIUM A NR 7616/2024, NOTARIUSZ ANNA STAROSZCZUK, 83-000 PRUSZCZ GDAŃSKI, UL. FRYDERYKA CHOPINA NR 12, NOTARIUSZ ANNA STAROSZCZUK, ZMIANA PARAGRAFU 6 UMOWY SPÓŁKI.
Activities
Main activity
72.19.ZOther research and experimental development on natural sciences and engineering
General codes (divisions and groups)
General codes indicate a PKD division or group without a specific subclass.
Address and contact
- Address
- UL. STRASZYŃSKA, 10, 80-180, GDAŃSK, POLSKA
- Voivodeship
- POMORSKIE
- District
- GDAŃSK
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- AE:PL-12797-55250-HAGWI-35
Risk and payment profile - Vortex
Credibility rating
89.2 / 100
Very good credibility
Insolvency risk
Very low
Low threat
Closure risk
1
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organizational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
4
4/17 yrs
Board changes
1
1/17 yrs
PKD changes
3
3/17 yrs
Name changes
0
0/17 yrs
Data from 17 years of registry activity.
Credibility history
Payment reliability score from 2018–2024
Current: A (89/100)
Trend: stable (+1.5 pts/year)
Very high payment credibility - the company shows strong financial indicators and a history of on-time payments. Trading with it carries minimal risk.
Trade credit limit history
Standard limit from 2018–2024
Current: 6.1 M PLN
Safe: 3.3 M PLN
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Operational status - Vortex
Founded
April 7, 2009
17 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
GDAŃSK
POMORSKIE
Primary PKD
72.19.Z
Other research and experimental development on natural sciences and…
Share capital
50.0 K PLN
80 shares total
Shareholders
1
shareholder
Board
1 person
Proxies: 1
Filed years
7 years
2018–2024
Registry entries
46
latest: July 6, 2026
Revenue
41.6 M PLN
2024
Net profit
3.0 M PLN
2024
Assets
14.0 M PLN
2024
Equity
10.3 M PLN
2024
EBITDA
4.2 M PLN
2024
Valuation
26.3 M PLN
High confidence
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - Vortex.
No ratings
Related articles
News
Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase regarding BCX-CM-J - Europe's first veterinary cell-therapy drug from mesenchymal stem cells for dogs with osteoarthritis. Responses to the final EMA questions are due in May 2026; the CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. Pre-commercial biotech: 2024 closed with a PLN 14.9 m loss on zero revenue; cash of PLN 33.6 m at year-end. Trigon DM maintained a buy rating with a price target of PLN 127.2.
News
Captor Therapeutics: PLN 36 m of cash at 30 September 2025, runway to mid-2026 - clinical data versus the cash clock
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) - a pre-commercial biotech specialising in TPD (Targeted Protein Degradation) - closed Q3 2025 with PLN 36 m of cash and grants securing financing to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I - the first patient dosed at Barcelona Clinic Liver Cancer. CT-03 (MCL-1 degrader) nearing clinical entry. Without a new R&D partnership or equity issuance in 2026, the company will need additional financing.
